Compass Therapeutics, Inc. SEC filings CMPX

Compass Therapeutics, Inc. has 359 filings in SEC EDGAR's recent list, going back to May 30, 2018. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Compass Therapeutics, Inc. SEC filings
Form Description Filed Period
8-K Current report
Regulation FD disclosure
Sep 22, 2026 Sep 22, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 6, 2026 Aug 6, 2026
8-K Current report
Regulation FD disclosure
Jul 1, 2026 Jul 1, 2026
8-K Current report
Bylaw or fiscal year change
Jun 23, 2026 Jun 22, 2026
8-K Current report
Shareholder vote results
Jun 11, 2026 Jun 10, 2026
10-Q Quarterly report May 5, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 5, 2026 May 5, 2026
ARS Annual report to shareholders Apr 29, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 29, 2026 —
DEF 14A Proxy statement Apr 29, 2026 Jun 10, 2026
8-K Current report
Regulation FD disclosure, Other events
Apr 27, 2026 Apr 27, 2026
S-8 Employee stock plan registration Mar 12, 2026 —
10-K Annual report Mar 5, 2026 Dec 31, 2025
8-K Current report
Results of operations
Mar 5, 2026 Mar 5, 2026
EFFECT Filing Jan 7, 2026 —
8-K Current report
Results of operations, Other events
Jan 6, 2026 Jan 6, 2026
CORRESP Letter to the SEC Jan 5, 2026 —
UPLOAD Letter from the SEC Jan 2, 2026 —
DEL AM Filing Dec 31, 2025 —
S-3 Shelf registration Dec 30, 2025 —
10-Q Quarterly report Nov 5, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 5, 2025 Nov 5, 2025
8-K Current report
Material agreement, Other events
Aug 13, 2025 Aug 12, 2025
424B5 Prospectus supplement Aug 13, 2025 —
424B5 Prospectus supplement Aug 12, 2025 —
10-Q Quarterly report Aug 11, 2025 Jun 30, 2025
8-K Current report
Results of operations, Regulation FD disclosure
Aug 11, 2025 Aug 11, 2025
8-K Current report
Shareholder vote results
Jun 12, 2025 Jun 11, 2025
10-Q Quarterly report May 8, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 8, 2025 May 8, 2025
DEFA14A Additional proxy material Apr 29, 2025 —
ARS Annual report to shareholders Apr 29, 2025 Dec 31, 2024
DEF 14A Proxy statement Apr 29, 2025 Jun 11, 2025
8-K Current report
Regulation FD disclosure, Other events
Apr 1, 2025 Apr 1, 2025
S-8 Employee stock plan registration Mar 27, 2025 —
10-K Annual report Feb 27, 2025 Dec 31, 2024
8-K Current report
Results of operations
Feb 27, 2025 Feb 27, 2025
8-K Current report
Results of operations, Other events
Jan 8, 2025 Jan 8, 2025
8-K Current report
Officer or director change, Regulation FD disclosure
Dec 10, 2024 Dec 9, 2024
10-Q Quarterly report Nov 12, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 12, 2024 Nov 12, 2024
EFFECT Filing Sep 6, 2024 —
CORRESP Letter to the SEC Sep 4, 2024 —
UPLOAD Letter from the SEC Sep 3, 2024 —
S-3 Shelf registration Aug 30, 2024 —
10-Q Quarterly report Aug 12, 2024 Jun 30, 2024
8-K Current report
Results of operations
Aug 12, 2024 Aug 12, 2024
8-K Current report
Shareholder vote results
Jun 17, 2024 Jun 13, 2024
DEFA14A Additional proxy material May 29, 2024 —
8-K Current report
Officer or director change, Regulation FD disclosure
May 28, 2024 May 28, 2024
10-Q Quarterly report May 13, 2024 Mar 31, 2024
8-K Current report
Results of operations
May 13, 2024 May 13, 2024
ARS Annual report to shareholders Apr 29, 2024 Dec 31, 2023
DEFA14A Additional proxy material Apr 29, 2024 —
DEF 14A Proxy statement Apr 29, 2024 Jun 13, 2024
8-K Current report
Regulation FD disclosure
Apr 25, 2024 Apr 25, 2024
10-K Annual report Mar 21, 2024 Dec 31, 2023
8-K Current report
Results of operations
Mar 21, 2024 Mar 21, 2024
8-K Current report
Officer or director change, Other events
Jan 9, 2024 Jan 8, 2024
8-K Current report
Results of operations, Regulation FD disclosure
Jan 5, 2024 Jan 5, 2024
10-Q Quarterly report Nov 9, 2023 Sep 30, 2023
8-K Current report
Results of operations
Nov 9, 2023 Nov 9, 2023
10-Q Quarterly report Aug 3, 2023 Jun 30, 2023
8-K Current report
Results of operations
Aug 3, 2023 Aug 3, 2023
8-K Current report
Shareholder vote results
Jun 15, 2023 Jun 15, 2023
10-Q Quarterly report May 4, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 4, 2023 May 4, 2023
ARS Annual report to shareholders Apr 27, 2023 Dec 31, 2022
DEFA14A Additional proxy material Apr 27, 2023 —
DEF 14A Proxy statement Apr 27, 2023 Jun 15, 2023
8-K Current report
Officer or director change
Apr 24, 2023 Apr 21, 2023
10-K Annual report Mar 15, 2023 Dec 31, 2022
8-K Current report
Regulation FD disclosure
Mar 10, 2023 Mar 10, 2023
8-K Current report
Officer or director change
Feb 24, 2023 Feb 20, 2023
8-K Current report
Officer or director change
Feb 10, 2023 Feb 8, 2023
424B3 Prospectus Jan 24, 2023 —
EFFECT Filing Jan 20, 2023 —
8-K Current report
Other events
Jan 19, 2023 Jan 19, 2023
CORRESP Letter to the SEC Jan 19, 2023 —
CORRESP Letter to the SEC Jan 17, 2023 —
CORRESP Letter to the SEC Jan 13, 2023 —
UPLOAD Letter from the SEC Dec 7, 2022 —
S-3 Shelf registration Dec 2, 2022 —
8-K Current report
Officer or director change
Nov 29, 2022 Nov 29, 2022
10-Q Quarterly report Nov 9, 2022 Sep 30, 2022
8-K Current report
Material agreement, Unregistered share sale, Officer or director change
Nov 2, 2022 Nov 2, 2022
8-K Current report
Officer or director change
Aug 19, 2022 Aug 17, 2022
424B5 Prospectus supplement Aug 1, 2022 —
8-K Current report
Material agreement, Agreement ended
Aug 1, 2022 Jul 22, 2022
10-Q Quarterly report Aug 1, 2022 Jun 30, 2022
8-K Current report
Shareholder vote results
May 31, 2022 May 31, 2022
DEFA14A Additional proxy material May 18, 2022 —
10-Q Quarterly report May 9, 2022 Mar 31, 2022
8-K Current report
Regulation FD disclosure
May 4, 2022 May 4, 2022
DEF 14A Proxy statement Apr 28, 2022 May 24, 2022
8-K Current report
Officer or director change
Apr 26, 2022 Apr 22, 2022
10-K Annual report Mar 18, 2022 Dec 31, 2021
8-K Current report
Officer or director change
Feb 25, 2022 Feb 22, 2022
8-K Current report
Other events
Jan 20, 2022 Jan 20, 2022
8-K Current report
Officer or director change
Dec 21, 2021 Dec 20, 2021
424B5 Prospectus supplement Dec 15, 2021 —
424B5 Prospectus supplement Dec 15, 2021 —
10-Q Quarterly report Nov 12, 2021 Sep 30, 2021
8-K Current report
Material agreement, Other events
Nov 3, 2021 Nov 1, 2021
424B5 Prospectus supplement Nov 3, 2021 —
CERT Filing Nov 1, 2021 —
424B5 Prospectus supplement Nov 1, 2021 —
8-A12B Filing Nov 1, 2021 —
8-K Current report
Results of operations, Other events
Nov 1, 2021 Nov 1, 2021
8-K Current report
Other events
Oct 8, 2021 Oct 8, 2021
10-Q Quarterly report Aug 16, 2021 Jun 30, 2021
8-K/A Amended current report Aug 5, 2021 Jun 25, 2021
EFFECT Filing Jul 20, 2021 —
CORRESP Letter to the SEC Jul 16, 2021 —
UPLOAD Letter from the SEC Jul 15, 2021 —
S-3 Shelf registration Jul 9, 2021 —
8-K Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Officer or director change, Other events
Jun 30, 2021 Jun 25, 2021
8-K Current report
Shareholder vote results
Jun 4, 2021 Jun 3, 2021
8-K Current report
Material agreement, Regulation FD disclosure
May 13, 2021 May 13, 2021
424B3 Prospectus Apr 30, 2021 —
10-Q Quarterly report Apr 30, 2021 Mar 31, 2021
DEF 14A Proxy statement Apr 29, 2021 Jun 3, 2021
8-K Current report
Officer or director change
Apr 19, 2021 Apr 14, 2021
424B3 Prospectus Mar 11, 2021 —
EFFECT Filing Mar 8, 2021 —
POS AM Filing Mar 5, 2021 —
10-K Annual report Mar 5, 2021 Dec 31, 2020
S-8 Employee stock plan registration Jan 14, 2021 —
8-K Current report
Material agreement, New debt
Dec 17, 2020 Dec 12, 2020
RW Registration withdrawal Nov 13, 2020 —
CERT 8a cert Nov 12, 2020 —
8-A12B Filing Nov 10, 2020 —
424B3 Prospectus Nov 9, 2020 —
S-1/A Amended registration statement Nov 9, 2020 —
10-Q Quarterly report Nov 9, 2020 Sep 30, 2020
S-1 Registration statement Oct 19, 2020 —
EFFECT Filing Sep 25, 2020 —
424B3 Prospectus Sep 25, 2020 —
CORRESP Letter to the SEC Sep 23, 2020 —
DRS Filing Sep 23, 2020 —
S-1/A Amended registration statement Sep 18, 2020 —
8-K Current report
Officer or director change
Sep 15, 2020 Sep 10, 2020
UPLOAD Letter from the SEC Aug 14, 2020 —
10-Q Quarterly report Aug 13, 2020 Jun 30, 2020
S-1 Registration statement Aug 11, 2020 —
UPLOAD Letter from the SEC Aug 11, 2020 —
CORRESP Letter to the SEC Jul 31, 2020 —
8-K/A Amended current report
Acquisition or sale of assets
Jul 31, 2020 Jun 17, 2020
UPLOAD Letter from the SEC Jul 17, 2020 —
D Filing Jul 1, 2020 —
D Filing Jul 1, 2020 —
8-K Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change
Jun 23, 2020 Jun 17, 2020
10-K Annual report Jun 8, 2020 Mar 31, 2020
SC 14F1/A Form sc 14f1/a May 28, 2020 —
SC 14F1 Schedule 14f-1 May 27, 2020 —
10-Q Quarterly report Feb 14, 2020 Dec 31, 2019
10-Q Quarterly report Nov 13, 2019 Sep 30, 2019
10-Q Quarterly report Aug 13, 2019 Jun 30, 2019
10-K Annual report Jul 1, 2019 Mar 31, 2019
10-Q Quarterly report Feb 14, 2019 Dec 31, 2018
10-Q Quarterly report Nov 14, 2018 Sep 30, 2018
10-Q Quarterly report Aug 14, 2018 Jun 30, 2018
10-12G General form for registration of securities May 30, 2018 —

Showing 164 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CMPX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1738021
Former names
Olivia Ventures, Inc. (until Jun 8, 2020)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.